Cite
Renneville A, Gasser JA, Grinshpun DE, et al. Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies. Blood Cancer Discov. 2021;2(3):250-265doi: 10.1158/2643-3230.BCD-20-0105.
Renneville, A., Gasser, J. A., Grinshpun, D. E., Jean Beltran, P. M., Udeshi, N. D., Matyskiela, M. E., Clayton, T., McConkey, M., Viswanathan, K., Tepper, A., Guirguis, A. A., Sellar, R. S., Cotteret, S., Marzac, C., Saada, V., De Botton, S., Kiladjian, J. J., Cayuela, J. M., Rolfe, M., Chamberlain, P. P., Carr, S. A., & Ebert, B. L. (2021). Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies. Blood cancer discovery, 2(3), 250-265. https://doi.org/10.1158/2643-3230.BCD-20-0105
Renneville, Aline, et al. "Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies." Blood cancer discovery vol. 2,3 (2021): 250-265. doi: https://doi.org/10.1158/2643-3230.BCD-20-0105
Renneville A, Gasser JA, Grinshpun DE, Jean Beltran PM, Udeshi ND, Matyskiela ME, Clayton T, McConkey M, Viswanathan K, Tepper A, Guirguis AA, Sellar RS, Cotteret S, Marzac C, Saada V, De Botton S, Kiladjian JJ, Cayuela JM, Rolfe M, Chamberlain PP, Carr SA, Ebert BL. Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies. Blood Cancer Discov. 2021 May;2(3):250-265. doi: 10.1158/2643-3230.BCD-20-0105. Epub 2021 Mar 10. PMID: 34027417; PMCID: PMC8133393.
Copy
Download .nbib